Advanced search
Publication Cover
Cancer Management and Research Volume 10, 2018 - Issue
Submit an article Journal homepage
199
Views
29
CrossRef citations to date
0
Altmetric
Original Research

CDK7 inhibition is a novel therapeutic strategy against GBM both in vitro and in vivo

Wei Meng1 Department of Pediatric Neurosurgery, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China, [email protected], [email protected]
,
Jiajia Wang1 Department of Pediatric Neurosurgery, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China, [email protected], [email protected]
,
Baocheng Wang1 Department of Pediatric Neurosurgery, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China, [email protected], [email protected]
,
Fang Liu2 Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China, [email protected]
,
Meng Li2 Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China, [email protected]
,
Yang Zhao1 Department of Pediatric Neurosurgery, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China, [email protected], [email protected]
,
Chenran Zhang1 Department of Pediatric Neurosurgery, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China, [email protected], [email protected]
,
Qifeng Li1 Department of Pediatric Neurosurgery, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China, [email protected], [email protected]
,
Juxiang Chen3 Department of Neurosurgery, Changzheng Hospital, Second Military Medical University, Shanghai, People’s Republic of China
,
Liye Zhang4 Zhang’s Laboratory, School of Life Science and Technology, Shanghai Tech University, Shanghai, People’s Republic of China
,
Yujie Tang1 Department of Pediatric Neurosurgery, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China, [email protected], [email protected];2 Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, Department of Pathophysiology, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China, [email protected]Correspondence[email protected]
&
Jie Ma1 Department of Pediatric Neurosurgery, Xin Hua Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China, [email protected], [email protected]Correspondence[email protected]
 show all
Pages 5747-5758 | Published online: 15 Nov 2018

Citations (29)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Markéta Kovalová, Joseph Peter Baraka, Václav Mik, Radek Jorda, Lei Luo, Hao Shao & Vladimír Kryštof. (2023) A patent review of cyclin-dependent kinase 7 (CDK7) inhibitors (2018-2022). Expert Opinion on Therapeutic Patents 33:2, pages 67-87.
Read now

Articles from other publishers (28)

Ying Gong & Huiping Li. (2024) CDK7 in breast cancer: mechanisms of action and therapeutic potential. Cell Communication and Signaling 22:1.
Crossref
Anastasia V. Vasileva, Marina G. Gladkova, German A. Ashniev, Ekaterina D. Osintseva, Alexey V. Orlov, Ekaterina V. Kravchuk, Anna V. Boldyreva, Alexander G. Burenin, Petr I. Nikitin & Natalia N. Orlova. (2024) Super-Enhancers and Their Parts: From Prediction Efforts to Pathognomonic Status. International Journal of Molecular Sciences 25:6, pages 3103.
Crossref
Isha Bhutada, Fatema Khambati, Shi-Yuan Cheng, Deanna M Tiek, Derek Duckett, Harshani Lawrence, Michael A Vogelbaum, Qianxing Mo, Srikumar P Chellappan & Jaya Padmanabhan. (2024) CDK7 and CDK9 inhibition interferes with transcription, translation, and stemness, and induces cytotoxicity in GBM irrespective of temozolomide sensitivity. Neuro-Oncology 26:1, pages 70-84.
Crossref
Xiaoping Hu, Jingdun Xie, Yilin Yang, Ziyi Qiu, Weicheng Lu, Xudong Lin & Bingzhe Xu. (2023) Multi-Target Neural Differentiation (MTND) Therapeutic Cocktail to Suppress Brain Tumor. International Journal of Molecular Sciences 24:15, pages 12329.
Crossref
MengTing Wang, QingYang Chen, ShuJie Wang, Han Xie, Jun Liu, RuiXiang Huang, YuFei Xiang, YanYi Jiang, DaSheng Tian & ErBao Bian. (2023) Super-enhancers complexes zoom in transcription in cancer. Journal of Experimental & Clinical Cancer Research 42:1.
Crossref
Zhen-Chu Tang, Qiang Qu, Xin-Qi Teng, Hai-Hui Zhuang, Wei-Xin Xu & Jian Qu. (2023) Bibliometric analysis of evolutionary trends and hotspots of super-enhancers in cancer. Frontiers in Pharmacology 14.
Crossref
Shinsuke Araki, Momoko Ohori & Masato Yugami. (2023) Targeting pre-mRNA splicing in cancers: roles, inhibitors, and therapeutic opportunities. Frontiers in Oncology 13.
Crossref
Xiaowei Du, Hao Wang, Jing Xu, Yufei Zhang, Tingsong Chen & Gao Li. (2023) Profiling and integrated analysis of transcriptional addiction gene expression and prognostic value in hepatocellular carcinoma. Aging.
Crossref
Hai-Hui Zhuang, Qiang Qu, Xin-Qi Teng, Ying-Huan Dai & Jian Qu. (2023) Superenhancers as master gene regulators and novel therapeutic targets in brain tumors. Experimental & Molecular Medicine 55:2, pages 290-303.
Crossref
Matthew Zatzman, Fabio FuligniRyan Ripsman, Tannu Suwal, Federico Comitani, Lisa-Monique EdwardRob Denroche, Gun Ho JangFaiyaz NottaSteven GallingerSaravana P. Selvanathan, Jeffrey A. Toretsky, Matthew D. HellmannUri TaboriAnnie HuangAdam Shlien. (2022) Widespread hypertranscription in aggressive human cancers. Science Advances 8:47.
Crossref
Woo Kyung Lee Doolittle, Li ZhaoSheue-Yann Cheng. (2022) Blocking CDK7-Mediated NOTCH1-cMYC Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer. Thyroid 32:8, pages 937-948.
Crossref
Xiaoyang Li, Dylan C. Dean, Jin Yuan, Thomas H. Temple, Jonathan C. Trent, Andrew E. Rosenberg, Shengji Yu, Francis J. Hornicek & Zhenfeng Duan. (2022) Inhibition of CDK7-dependent transcriptional addiction is a potential therapeutic target in synovial sarcoma. Biomedicine & Pharmacotherapy 149, pages 112888.
Crossref
Jin Yuan, Xiaoyang Li & Shengji Yu. (2022) CDK7-dependent transcriptional addiction in bone and soft tissue sarcomas: Present and Future. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1877:2, pages 188680.
Crossref
Jiajia Wang, Xin Ma & Jie Ma. (2021) Identification of Four Enhancer-Associated Genes as Risk Signature for Diffuse Glioma Patients. Journal of Molecular Neuroscience 72:2, pages 410-419.
Crossref
Chiara Naro, Pamela Bielli & Claudio Sette. (2021) Oncogenic dysregulation of pre‐mRNA processing by protein kinases: challenges and therapeutic opportunities. The FEBS Journal 288:21, pages 6250-6272.
Crossref
Nadia Al-Sammarraie & Swapan K. Ray. (2021) Applications of CRISPR-Cas9 Technology to Genome Editing in Glioblastoma Multiforme. Cells 10:9, pages 2342.
Crossref
Viktorija Juric, Lance Hudson, Joanna Fay, Cathy E. Richards, Hanne Jahns, Maïté Verreault, Franck Bielle, Ahmed Idbaih, Martine L. M. Lamfers, Ann M. Hopkins, Markus Rehm & Brona M. Murphy. (2021) Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation. Cell Death & Disease 12:8.
Crossref
Nathan A Dahl & Rajeev Vibhakar. (2021) Converging evidence for inhibition of transcriptional control in high-grade gliomas. Neuro-Oncology 23:8, pages 1225-1227.
Crossref
Tuersunayi Abudureheman, Jing Xia, Ming-Hao Li, Hang Zhou, Wei-Wei Zheng, Neng Zhou, Rong-Yi Shi, Jian-Min Zhu, Li-Ting Yang, Li Chen, Liang Zheng, Kai Xue, Kai Qing & Cai-Wen Duan. (2021) CDK7 Inhibitor THZ1 Induces the Cell Apoptosis of B-Cell Acute Lymphocytic Leukemia by Perturbing Cellular Metabolism. Frontiers in Oncology 11.
Crossref
Christin Riess, Nina Irmscher, Inken Salewski, Daniel Strüder, Carl-Friedrich Classen, Christina Große-Thie, Christian Junghanss & Claudia Maletzki. (2020) Cyclin-dependent kinase inhibitors in head and neck cancer and glioblastoma—backbone or add-on in immune-oncology?. Cancer and Metastasis Reviews 40:1, pages 153-171.
Crossref
Vaishnavi Sundar, Sanjana Vimal, M.s. Sai Mithlesh, Anupam Dutta, Ramasamy Tamizhselvi & Venkatraman Manickam. (2021) Transcriptional cyclin-dependent kinases as the mediators of inflammation-a review. Gene 769, pages 145200.
Crossref
Georgina P. Sava, Hailing Fan, R. Charles Coombes, Lakjaya Buluwela & Simak Ali. (2020) CDK7 inhibitors as anticancer drugs. Cancer and Metastasis Reviews 39:3, pages 805-823.
Crossref
Enyuan Shang, Trang T. T. Nguyen, Chang Shu, Mike-Andrew Westhoff, Georg Karpel-Massler & Markus D. Siegelin. (2020) Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma. Cancers 12:8, pages 2137.
Crossref
Jordan L Kohlmeyer, David J Gordon, Munir R Tanas, Varun Monga, Rebecca D Dodd & Dawn E Quelle. (2020) CDKs in Sarcoma: Mediators of Disease and Emerging Therapeutic Targets. International Journal of Molecular Sciences 21:8, pages 3018.
Crossref
Meng Cheng, Zheng Wei Zhang, Xing Hu Ji, Yadi Xu, Erbao Bian & Bing Zhao. (2020) Super-enhancers: A new frontier for glioma treatment. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1873:2, pages 188353.
Crossref
Jihye Kim, Young-Jae Cho, Ji-Yoon Ryu, Ilseon Hwang, Hee Dong Han, Hyung Jun Ahn, Woo Young Kim, Hanbyoul Cho, Joon-Yong Chung, Stephen M. Hewitt, Jae-Hoon Kim, Byoung-Gie Kim, Duk-Soo Bae, Chel Hun Choi & Jeong-Won Lee. (2020) CDK7 is a reliable prognostic factor and novel therapeutic target in epithelial ovarian cancer. Gynecologic Oncology 156:1, pages 211-221.
Crossref
Feda H. Hamdan & Steven A. Johnsen. (2019) Perturbing Enhancer Activity in Cancer Therapy. Cancers 11:5, pages 634.
Crossref
Yi He, Wenyong Long & Qing Liu. (2019) Targeting Super-Enhancers as a Therapeutic Strategy for Cancer Treatment. Frontiers in Pharmacology 10.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.